Literature DB >> 6975059

Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age.

P Patamasucon, S Kaojarern, H Kusmiesz, J D Nelson.   

Abstract

We studied the pharmacokinetics of erythromycin estolate and ethylsuccinate suspensions in infants under 4 months of age who were being treated for chlamydial infections or pertussis. We conducted our studies after the initial dose of 10 mg/kg and subsequently during steady-state treatment. The estolate preparation resulted in higher peak concentrations in sera, and its absorption and elimination half-lives were longer. Peak concentrations occurred 3 h after a dose with the estolate preparation and 1 h after a dose with the ethylsuccinate preparation. The area under the curve for the estolate preparation was about three times greater than that for the ethylsuccinate preparation. Based on these findings, we recommend that erythromycin estolate suspensions be given to young infants at 8- or 12-h intervals (30 mg/kg per day in three divided doses or 20 mg/kg per day in two divided doses) and that erythromycin ethylsuccinate is best given at 6-h intervals (40 mg/kg per day in four divided doses).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975059      PMCID: PMC181514          DOI: 10.1128/AAC.19.5.736

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  STUDIES OF PREMATURES GIVEN ERYTHROMYCIN ESTOLATE.

Authors:  L BURNS; J HODGMAN
Journal:  Am J Dis Child       Date:  1963-09

2.  Erythromycin--a review.

Authors:  J O FORFAR; A F MACCABE
Journal:  Antibiot Chemother       Date:  1957

3.  Antimicrobial activity of several antibiotics and a sulfonamide against Chlamydia trachomatis organisms in cell culture.

Authors:  C C Kuo; S P Wang; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

Review 4.  Erythromycin: a review of its uses in pediatric practice.

Authors:  C M Ginsburg; H F Eichenwald
Journal:  J Pediatr       Date:  1976-12       Impact factor: 4.406

5.  Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability.

Authors:  G H McCracken; C M Ginsburg; J C Clahsen; M L Thomas
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

6.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

7.  Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.

Authors:  A R DiSanto; K Y Tserng; D J Chodos; K A DeSante; K S Albert; J G Wagner
Journal:  J Clin Pharmacol       Date:  1980-07       Impact factor: 3.126

8.  Antibacterial activity of 2'-esters of erythromycin.

Authors:  P L Tardrew; J C Mao; D Kenney
Journal:  Appl Microbiol       Date:  1969-08
  8 in total
  7 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

2.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

Review 3.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 4.  The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental?

Authors:  Manfred Hauben; Guy W Amsden
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 6.  Mycoplasmas and ureaplasmas as neonatal pathogens.

Authors:  Ken B Waites; Brenda Katz; Robert L Schelonka
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 7.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.